[Form 4] VERACYTE, INC. Insider Trading Activity

Rhea-AI Filing Summary

Robert S. Epstein, a director of Veracyte, Inc. (VCYT), reported transactions on a Form 4 dated 10/01/2025. He exercised 10,000 stock options with an exercise price of $7.94, resulting in 10,000 shares issued, and subsequently sold 21,473 common shares at a weighted average sale price of $35.0768 (individual sales ranged $35.00–$35.30). The Form shows his beneficial ownership changing from 83,919 shares after the option exercise to 62,446 shares following the sale. The transactions were made under a Rule 10b5-1 plan adopted June 5, 2025, and the Form was signed by an attorney-in-fact on 10/03/2025.

Positive

• Transactions disclosed under a Rule 10b5-1 plan (adopted June 5, 2025), indicating pre-planned trades
• Full price range disclosed for sales ($35.00–$35.30) and weighted average sale price provided ($35.0768)

Negative

• Director sold 21,473 shares, reducing beneficial ownership from 83,919 to 62,446
• Derivative holdings reported as 0 following the transactions (options exercised and not retained)

Insights

Securities Compliance Specialist

Insider transactions executed under a pre-established 10b5-1 plan; filings align with typical compliance practice.

The reporting shows a clear exercise of 10,000 options at $7.94 and an immediately disclosed sale of 21,473 shares at a weighted average of $35.0768. The Form 4 explicitly states the trades were made pursuant to a Rule 10b5-1 plan adopted June 5, 2025, which documents pre-planned trades and is commonly used to mitigate timing concerns under insider trading rules.

The filing was signed by an attorney-in-fact on 10/03/2025, which is a standard execution method; all key transaction details and price ranges are disclosed in the Form.

Corporate Governance Analyst

Director reduced beneficial ownership while exercising options; disclosures show net share decline.

The exercise created 10,000 newly acquired shares, but subsequent sales reduced the director's beneficial holdings from 83,919 to 62,446. This represents a net decline of 21,473 shares held after the transactions reported.

All transactions and price ranges are disclosed on the Form, providing transparency on insider holdings and liquidity actions by a board member.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

EPSTEIN ROBERT S

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M(1)		10,000	A	$7.94	83,919	D
Common Stock	10/01/2025		S(1)		21,473	D	$35.0768(2)	62,446	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.94	10/01/2025		M(1)			10,000	06/07/2018	06/07/2027	Common Stock	10,000	$0	0	D

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 5, 2025.

2. Represents weighted average sales price. Sale prices for the transactions range from $35.00 to $35.30. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Veracyte director Robert S. Epstein report on Form 4 (VCYT)?

He reported exercising 10,000 options at an exercise price of $7.94 and selling 21,473 shares at a weighted average price of $35.0768 on 10/01/2025.

Were the trades by Robert S. Epstein part of a pre-arranged plan?

Yes. The Form 4 states the transactions were made pursuant to a Rule 10b5-1 plan adopted June 5, 2025.

How did Epstein's beneficial ownership change after these transactions?

Beneficial ownership is shown as 83,919 shares after the option exercise and 62,446 shares after the sale, a net decrease of 21,473 shares.

What price range and weighted average were reported for the share sales?

Sale prices ranged from $35.00 to $35.30; the weighted average sale price reported is $35.0768.

Who signed the Form 4 and when was it filed?

The Form 4 was signed by an attorney-in-fact, Jonathan Wygant, on 10/03/2025.